scFv-Transferrin Fusion With Cleavable Linker for Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of specific targeting mechanisms, limiting their therapeutic efficacy and application.
Innovation Solution
A single-chain variable fragment (scFv) antibody is designed to conjugate with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis for enhanced cellular uptake and incorporating cleavable linkers that respond to specific cellular environments for targeted delivery and release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used, then effector functions and half-life are enhanced, but penetration across biological barriers is reduced
Solution Approach 1:
The patent segments the antibody into its functional components: the scFv fragment (25-30 kDa) provides penetration capability across biological barriers, while the Fc region (separately provided as a soluble protein) provides effector functions. This segmentation allows each component to optimize its specific function without compromising the other.
Solution Approach 2:
The patent uses transferrin as an intermediary protein that facilitates the transport of the scFv fragment across biological barriers. The scFv-transferrin conjugate utilizes transferrin receptor-mediated endocytosis to enhance cellular uptake, with the cleavable linker allowing controlled release of the scFv inside the cell.
2Length of moving object
If a scFv is used, then penetration across biological barriers is improved, but effector functions are lost
Solution Approach 1:
The patent merges the scFv fragment (which provides penetration) with the Fc region (which provides effector functions) in a functional combination. The scFv-transferrin conjugate enters cells via endocytosis, and the Fc region is subsequently provided to mediate effector functions, achieving both penetration and effector capability.
Solution Approach 2:
Transferrin serves as an intermediary that enables the scFv to cross biological barriers and enter cells, while the Fc region acts as a separate intermediary that provides effector functions. This multi-intermediary approach resolves the contradiction between penetration and effector functions.
3Ease of manufacture
If a scFv is used, then manufacturing ease and cost are reduced, but therapeutic efficacy is limited without transcytosis assistance
Solution Approach 1:
The patent incorporates transferrin as an intermediary protein that enhances the therapeutic efficacy of the scFv fragment. The scFv-transferrin conjugate utilizes transferrin receptor-mediated endocytosis to achieve enhanced cellular uptake and transcytosis, thereby improving therapeutic efficacy while maintaining the manufacturing advantages of scFv.
4Length of moving object
If antibodies cross cell walls, then delivery to target tissues is improved, but efficacy is reduced due to challenges in crossing barriers
Solution Approach 1:
The patent uses transferrin as an intermediary that facilitates the crossing of biological barriers. The scFv-transferrin conjugate exploits transferrin receptor-mediated endocytosis to achieve efficient transcytosis across the blood-brain barrier and other biological barriers, thereby improving both delivery and efficacy.
Solution Approach 2:
The patent changes the molecular weight parameter by using the smaller scFv fragment (25-30 kDa) instead of full-length antibodies (150 kDa), enabling easier penetration across biological barriers. The cleavable linker parameter allows controlled release inside cells, maintaining efficacy while facilitating barrier crossing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-transferrin conjugate achieves improved penetration across biological barriers, enhances therapeutic efficacy by reducing off-target effects, and allows for controlled release within target cells, thereby increasing the effectiveness of antibody-based treatments.
Implementation Method 1
utilizing transferrin receptor-mediated endocytosis for enhanced cellular uptake
Implementation Method 2
incorporating cleavable linkers that respond to specific cellular environments for targeted delivery and release
Data Source
AI summary
The efficacy and indication of tilavonemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.